NASDAQ:NAMS NewAmsterdam Pharma (NAMS) Stock Price, News & Analysis $16.40 +0.20 (+1.23%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$15.72▼$16.6150-Day Range$15.66▼$20.9952-Week Range$5.63▼$26.35Volume274,119 shsAverage Volume256,932 shsMarket Capitalization$1.48 billionP/E RatioN/ADividend YieldN/APrice Target$33.80 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get NewAmsterdam Pharma alerts: Email Address NewAmsterdam Pharma MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside106.1% Upside$33.80 Price TargetShort InterestBearish4.31% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.42Based on 6 Articles This WeekInsider TradingAcquiring Shares$86,300 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($2.06) to ($1.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.66 out of 5 starsMedical Sector395th out of 910 stocksPharmaceutical Preparations Industry176th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingNewAmsterdam Pharma has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageNewAmsterdam Pharma has only been the subject of 2 research reports in the past 90 days.Read more about NewAmsterdam Pharma's stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted4.31% of the float of NewAmsterdam Pharma has been sold short.Short Interest Ratio / Days to CoverNewAmsterdam Pharma has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in NewAmsterdam Pharma has recently increased by 20.71%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldNewAmsterdam Pharma does not currently pay a dividend.Dividend GrowthNewAmsterdam Pharma does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for NAMS. Previous Next 1.9 News and Social Media Coverage News SentimentNewAmsterdam Pharma has a news sentiment score of 0.42. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for NewAmsterdam Pharma this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added NewAmsterdam Pharma to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, NewAmsterdam Pharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $86,300.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders19.50% of the stock of NewAmsterdam Pharma is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions89.89% of the stock of NewAmsterdam Pharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about NewAmsterdam Pharma's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for NewAmsterdam Pharma are expected to grow in the coming year, from ($2.06) to ($1.60) per share.Price to Book Value per Share RatioNewAmsterdam Pharma has a P/B Ratio of 3.81. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about NewAmsterdam Pharma's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Deal MakerThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase, according to the NY Post. With a sky-high 150% turnover rate, the fast food industry is already grappling with labor issues before taking into account these wage hikes. The industry will need a projected 1 million new workers every year through 2032.Learn more about this much-needed advancement and investment opportunity here. About NewAmsterdam Pharma Stock (NASDAQ:NAMS)NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.Read More NAMS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart NAMS Stock News HeadlinesSeptember 7 at 9:16 AM | finance.yahoo.comWhile institutions own 29% of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS), private equity firms are its largest shareholders with 47% ownershipSeptember 7 at 6:55 AM | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Rating Reiterated by Royal Bank of CanadaSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.September 6 at 4:32 PM | globenewswire.comNewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)August 30, 2024 | globenewswire.comNewAmsterdam Pharma to Participate in Upcoming Investor Conferences in SeptemberAugust 29, 2024 | msn.comNeedham Initiates Coverage of NewAmsterdam Pharma Company N.V. (NAMS) with Buy RecommendationAugust 29, 2024 | americanbankingnews.comNewAmsterdam Pharma (NASDAQ:NAMS) Receives New Coverage from Analysts at Needham & Company LLCAugust 29, 2024 | benzinga.comNewAmsterdam Pharma (NASDAQ:NAMS) Stock Quotes, Forecast and News SummarySeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 28, 2024 | markets.businessinsider.comBuy Rating Affirmed for NewAmsterdam Pharma on Strong Prospects for Cholesterol Drug obicetrapibAugust 28, 2024 | markets.businessinsider.comTD Cowen Keeps Their Buy Rating on NewAmsterdam Pharma Company (NAMS)August 28, 2024 | finance.yahoo.comNewAmsterdam Pharma's Cholesterol Drug To See Blockbuster Sales, Bullish Analyst Sees Massive UpsideAugust 28, 2024 | americanbankingnews.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Target Price at $33.25August 28, 2024 | americanbankingnews.comBrokerages Set NewAmsterdam Pharma (NASDAQ:NAMS) Price Target at $33.25August 13, 2024 | markets.businessinsider.comAnalysts Conflicted on These Healthcare Names: GoodRx Holdings (GDRX), NewAmsterdam Pharma Company (NAMS) and uniQure (QURE)August 8, 2024 | markets.businessinsider.comRBC Capital Reaffirms Their Buy Rating on NewAmsterdam Pharma Company (NAMS)August 8, 2024 | markets.businessinsider.comStrong Buy Rating for NewAmsterdam Pharma Backed by Obicetrapib’s Efficacy and Market PotentialAugust 8, 2024 | finance.yahoo.comNewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial ResultsSee More Headlines Receive NAMS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:NAMS CUSIPN/A CIK1936258 Webwww.newamsterdampharma.com Phone352062971FaxN/AEmployees4Year FoundedN/APrice Target and Rating Average Stock Price Target$33.80 High Stock Price Target$37.00 Low Stock Price Target$30.00 Potential Upside/Downside+106.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio9.83 Quick Ratio9.83 Sales & Book Value Annual Sales$7.42 million Price / Sales198.76 Cash FlowN/A Price / Cash FlowN/A Book Value$4.30 per share Price / Book3.81Miscellaneous Outstanding Shares89,977,000Free Float72,431,000Market Cap$1.48 billion OptionableOptionable BetaN/A The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Michael Harvey Davidson FACC (Age 68)Facp., M.D., CEO, President, Executive Board Member & Director Comp: $882kDr. Johannes Jacob Pieter Kastelein FESC (Age 70)M.D., Ph.D., Founder, Chief Scientific Officer, Member of Executive Board & Director Comp: $677.76kMr. Mayur Amrat Somaiya (Age 51)Chief Financial Officer Comp: $130.58kMr. Douglas F. Kling (Age 51)Chief Operating Officer Mr. Jim JacobsonChief Legal Officer & SecretaryDr. Marc Ditmarsch M.D. (Age 57)Chief Development Officer Dr. Sheng Cui Ph.D.VP & Head of Chemistry Manufacturing and Controls (CMC)Ms. Annie NeildVP & Head of Regulatory AffairsMr. William Jones Jr. (Age 60)M.B.A., Chief Commercial Officer More ExecutivesKey CompetitorsOrganon & Co.NYSE:OGNBridgeBio PharmaNASDAQ:BBIONuvalentNASDAQ:NUVLKrystal BiotechNASDAQ:KRYSApellis PharmaceuticalsNASDAQ:APLSView All CompetitorsInsiders & InstitutionsMillennium Management LLCBought 217,902 shares on 8/15/2024Ownership: 1.295%Deerfield Management Company L.P. Series CBought 202,250 shares on 8/15/2024Ownership: 0.966%Affinity Asset Advisors LLCBought 136,955 shares on 8/15/2024Ownership: 0.470%Decheng Capital LLCBought 400,000 shares on 8/15/2024Ownership: 0.445%Marshall Wace LLPSold 93,549 shares on 8/14/2024Ownership: 0.024%View All Insider TransactionsView All Institutional Transactions NAMS Stock Analysis - Frequently Asked Questions How have NAMS shares performed this year? NewAmsterdam Pharma's stock was trading at $11.17 at the start of the year. Since then, NAMS shares have increased by 46.8% and is now trading at $16.40. View the best growth stocks for 2024 here. How were NewAmsterdam Pharma's earnings last quarter? NewAmsterdam Pharma (NASDAQ:NAMS) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.51) EPS for the quarter, beating analysts' consensus estimates of ($0.59) by $0.08. The company earned $2.28 million during the quarter, compared to analyst estimates of $2.20 million. Who are NewAmsterdam Pharma's major shareholders? NewAmsterdam Pharma's top institutional shareholders include Millennium Management LLC (1.30%), Deerfield Management Company L.P. Series C (0.97%), Affinity Asset Advisors LLC (0.47%) and Decheng Capital LLC (0.44%). Insiders that own company stock include James N Topper, Michael H Davidson, Louis G Lange and Johannes Jacob Piete Kastelein. View institutional ownership trends. How do I buy shares of NewAmsterdam Pharma? Shares of NAMS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:NAMS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredMy grim warning about AI stocksToday, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding NewAmsterdam Pharma Please log in to your account or sign up in order to add this asset to your watchlist. Share NewAmsterdam Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NAMS Stock Alerts